TSFAE24d:	Subjects With Treatment-emergent Adverse Events Toxicity Grade =3 With Frequency =[x]% in [Any Treatment Group] by System Organ Class and Preferred Term; Safety Analysis Set (Study jjcs - core)									
 	Active Study Agent 	Active Study Agent 	Active Study Agent 	Active Study Agent 	Active Study Agent 	Active Study Agent 	 	 	
 	Xanomeline High Dose 	Xanomeline High Dose 	Xanomeline Low Dose 	Xanomeline Low Dose 	Combined 	Combined 	Placebo 	Placebo 	
System Organ Class 	N=53 	N=53 	N=73 	N=73 	N=126 	N=126 	N=59 	N=59 	
 Preferred Term, n (%) 	AEs 	≥ Grade 3 AEs 	AEs 	≥ Grade 3 AEs 	AEs 	≥ Grade 3 AEs 	AEs 	≥ Grade 3 AEs 	
Subjects with ≥ 1 AE 	51 (96.2%) 	48 (90.6%) 	62 (84.9%) 	52 (71.2%) 	113 (89.7%) 	100 (79.4%) 	42 (71.2%) 	35 (59.3%) 	
 	 	 	 	 	 	 	 	 	
General disorders and administration site conditions 	26 (49.1%) 	23 (43.4%) 	38 (52.1%) 	26 (35.6%) 	64 (50.8%) 	49 (38.9%) 	16 (27.1%) 	10 (16.9%) 	
APPLICATION SITE PRURITUS 	13 (24.5%) 	8 (15.1%) 	18 (24.7%) 	8 (11.0%) 	31 (24.6%) 	16 (12.7%) 	4 (6.8%) 	4 (6.8%) 	
APPLICATION SITE ERYTHEMA 	10 (18.9%) 	6 (11.3%) 	11 (15.1%) 	7 (9.6%) 	21 (16.7%) 	13 (10.3%) 	2 (3.4%) 	0 	
APPLICATION SITE IRRITATION 	8 (15.1%) 	5 (9.4%) 	7 (9.6%) 	6 (8.2%) 	15 (11.9%) 	11 (8.7%) 	2 (3.4%) 	1 (1.7%) 	
APPLICATION SITE VESICLES 	4 (7.5%) 	3 (5.7%) 	4 (5.5%) 	3 (4.1%) 	8 (6.3%) 	6 (4.8%) 	0 	0 	
APPLICATION SITE DERMATITIS 	4 (7.5%) 	3 (5.7%) 	7 (9.6%) 	2 (2.7%) 	11 (8.7%) 	5 (4.0%) 	5 (8.5%) 	3 (5.1%) 	
FATIGUE 	5 (9.4%) 	2 (3.8%) 	5 (6.8%) 	3 (4.1%) 	10 (7.9%) 	5 (4.0%) 	0 	0 	
APPLICATION SITE SWELLING 	2 (3.8%) 	2 (3.8%) 	1 (1.4%) 	1 (1.4%) 	3 (2.4%) 	3 (2.4%) 	0 	0 	
APPLICATION SITE PERSPIRATION 	2 (3.8%) 	2 (3.8%) 	0 	0 	2 (1.6%) 	2 (1.6%) 	0 	0 	
OEDEMA PERIPHERAL 	1 (1.9%) 	1 (1.9%) 	1 (1.4%) 	0 	2 (1.6%) 	1 (0.8%) 	2 (3.4%) 	2 (3.4%) 	
 	 	 	 	 	 	 	 	 	
Skin and subcutaneous tissue disorders 	34 (64.2%) 	21 (39.6%) 	28 (38.4%) 	18 (24.7%) 	62 (49.2%) 	39 (31.0%) 	16 (27.1%) 	8 (13.6%) 	
PRURITUS 	20 (37.7%) 	11 (20.8%) 	14 (19.2%) 	9 (12.3%) 	34 (27.0%) 	20 (15.9%) 	6 (10.2%) 	2 (3.4%) 	
RASH 	5 (9.4%) 	4 (7.5%) 	9 (12.3%) 	6 (8.2%) 	14 (11.1%) 	10 (7.9%) 	4 (6.8%) 	2 (3.4%) 	
ERYTHEMA 	12 (22.6%) 	5 (9.4%) 	8 (11.0%) 	3 (4.1%) 	20 (15.9%) 	8 (6.3%) 	6 (10.2%) 	3 (5.1%) 	
HYPERHIDROSIS 	8 (15.1%) 	4 (7.5%) 	4 (5.5%) 	2 (2.7%) 	12 (9.5%) 	6 (4.8%) 	2 (3.4%) 	2 (3.4%) 	
SKIN IRRITATION 	4 (7.5%) 	2 (3.8%) 	4 (5.5%) 	2 (2.7%) 	8 (6.3%) 	4 (3.2%) 	3 (5.1%) 	2 (3.4%) 	
BLISTER 	1 (1.9%) 	1 (1.9%) 	2 (2.7%) 	2 (2.7%) 	3 (2.4%) 	3 (2.4%) 	0 	0 	
RASH PRURITIC 	2 (3.8%) 	2 (3.8%) 	1 (1.4%) 	1 (1.4%) 	3 (2.4%) 	3 (2.4%) 	0 	0 	
 	 	 	 	 	 	 	 	 	
Nervous system disorders 	18 (34.0%) 	11 (20.8%) 	18 (24.7%) 	11 (15.1%) 	36 (28.6%) 	22 (17.5%) 	5 (8.5%) 	4 (6.8%) 	
DIZZINESS 	8 (15.1%) 	4 (7.5%) 	8 (11.0%) 	3 (4.1%) 	16 (12.7%) 	7 (5.6%) 	0 	0 	
HEADACHE 	5 (9.4%) 	3 (5.7%) 	3 (4.1%) 	2 (2.7%) 	8 (6.3%) 	5 (4.0%) 	2 (3.4%) 	1 (1.7%) 	
 	 	 	 	 	 	 	 	 	
Gastrointestinal disorders 	14 (26.4%) 	10 (18.9%) 	10 (13.7%) 	7 (9.6%) 	24 (19.0%) 	17 (13.5%) 	7 (11.9%) 	5 (8.5%) 	
NAUSEA 	5 (9.4%) 	3 (5.7%) 	2 (2.7%) 	2 (2.7%) 	7 (5.6%) 	5 (4.0%) 	0 	0 	
DIARRHOEA 	2 (3.8%) 	1 (1.9%) 	3 (4.1%) 	3 (4.1%) 	5 (4.0%) 	4 (3.2%) 	3 (5.1%) 	2 (3.4%) 	
VOMITING 	5 (9.4%) 	4 (7.5%) 	2 (2.7%) 	0 	7 (5.6%) 	4 (3.2%) 	0 	0 	
SALIVARY HYPERSECRETION 	4 (7.5%) 	2 (3.8%) 	0 	0 	4 (3.2%) 	2 (1.6%) 	0 	0 	
 	 	 	 	 	 	 	 	 	
Cardiac disorders 	11 (20.8%) 	7 (13.2%) 	11 (15.1%) 	8 (11.0%) 	22 (17.5%) 	15 (11.9%) 	7 (11.9%) 	5 (8.5%) 	
SINUS BRADYCARDIA 	7 (13.2%) 	4 (7.5%) 	4 (5.5%) 	1 (1.4%) 	11 (8.7%) 	5 (4.0%) 	0 	0 	
ATRIAL FIBRILLATION 	1 (1.9%) 	1 (1.9%) 	2 (2.7%) 	2 (2.7%) 	3 (2.4%) 	3 (2.4%) 	0 	0 	
MYOCARDIAL INFARCTION 	3 (5.7%) 	0 	1 (1.4%) 	1 (1.4%) 	4 (3.2%) 	1 (0.8%) 	3 (5.1%) 	2 (3.4%) 	
 	 	 	 	 	 	 	 	 	
Infections and infestations 	9 (17.0%) 	7 (13.2%) 	6 (8.2%) 	5 (6.8%) 	15 (11.9%) 	12 (9.5%) 	14 (23.7%) 	8 (13.6%) 	
NASOPHARYNGITIS 	3 (5.7%) 	2 (3.8%) 	3 (4.1%) 	3 (4.1%) 	6 (4.8%) 	5 (4.0%) 	2 (3.4%) 	2 (3.4%) 	
 	 	 	 	 	 	 	 	 	
Respiratory, thoracic and mediastinal disorders 	7 (13.2%) 	5 (9.4%) 	6 (8.2%) 	4 (5.5%) 	13 (10.3%) 	9 (7.1%) 	5 (8.5%) 	4 (6.8%) 	
COUGH 	3 (5.7%) 	0 	4 (5.5%) 	3 (4.1%) 	7 (5.6%) 	3 (2.4%) 	1 (1.7%) 	1 (1.7%) 	
 	 	 	 	 	 	 	 	 	
Psychiatric disorders 	6 (11.3%) 	3 (5.7%) 	8 (11.0%) 	5 (6.8%) 	14 (11.1%) 	8 (6.3%) 	7 (11.9%) 	4 (6.8%) 	
CONFUSIONAL STATE 	1 (1.9%) 	0 	3 (4.1%) 	2 (2.7%) 	4 (3.2%) 	2 (1.6%) 	2 (3.4%) 	1 (1.7%) 	
 	 	 	 	 	 	 	 	 	
Musculoskeletal and connective tissue disorders 	4 (7.5%) 	4 (7.5%) 	5 (6.8%) 	2 (2.7%) 	9 (7.1%) 	6 (4.8%) 	2 (3.4%) 	2 (3.4%) 	
BACK PAIN 	2 (3.8%) 	2 (3.8%) 	1 (1.4%) 	0 	3 (2.4%) 	2 (1.6%) 	1 (1.7%) 	1 (1.7%) 	

Note: Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event. 	
Note: Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event.	
Note: Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event.	
Note: Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event.	
Note: Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event.	
Note: Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event.	
Note: Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event.	
Note: Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event.	
Note: Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event.	
Note: Adverse events are coded using MedDRA version 26.0; toxicity grade is evaluated according to NCI-CTCAE version 5.0.. 	: Adverse events are coded using MedDRA version 26; toxicity grade is evaluated according to NCI-CTCAE version 5..	: Adverse events are coded using MedDRA version 26; toxicity grade is evaluated according to NCI-CTCAE version 5..	: Adverse events are coded using MedDRA version 26; toxicity grade is evaluated according to NCI-CTCAE version 5..	: Adverse events are coded using MedDRA version 26; toxicity grade is evaluated according to NCI-CTCAE version 5..	: Adverse events are coded using MedDRA version 26; toxicity grade is evaluated according to NCI-CTCAE version 5..	: Adverse events are coded using MedDRA version 26; toxicity grade is evaluated according to NCI-CTCAE version 5..	: Adverse events are coded using MedDRA version 26; toxicity grade is evaluated according to NCI-CTCAE version 5..	: Adverse events are coded using MedDRA version 26; toxicity grade is evaluated according to NCI-CTCAE version 5..